The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures
Open accessAbstract
Our ability to evaluate outcomes which genuinely reflect patients' unmet needs, hopes and concerns is of pivotal importance. However, much current clinical research and practice falls short of this objective by selecting outcome measures which do not capture patient value to the fullest. In this Opinion, we discuss Patient-Centered Outcomes Measures (PCOMs), which have the potential to systematically incorporate patient perspectives to measure those outcomes that matter most to patients. We argue for greater multi-stakeholder collaboration to develop PCOMs, with rare disease patients and families at the center. Beyond advancing the science of patient input, PCOMs are powerful tools to translate care or observed treatment benefit into an 'interpretable' measure of patient benefit, and thereby help demonstrate clinical effectiveness. We propose mixed methods psychometric research as the best route to deliver fit-for-purpose PCOMs in rare diseases, as this methodology brings together qualitative and quantitative research methods in tandem with the explicit aim to efficiently utilise data from small samples. And, whether one opts to develop a brand-new PCOM or to select or adapt an existing outcome measure for use in a rare disease, the anchors remain the same: patients, their daily experience of the rare disease, their preferences, core concepts and values. Ultimately, existing value frameworks, registries, and outcomes-based contracts largely fall short of consistently measuring the full range of outcomes that matter to patients. We argue that greater use of PCOMs in rare diseases would enable a fast track to Patient-Centered Care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The disability paradox: high quality of life against all odds
Albrecht, G. L., & Devlieger, P. J. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(98)00411-0 · Cited by 2,064
Terwee, C. B., Mokkink, L. B., Knol, D. L., Ostelo, R. W. J. G., Bouter, L. M., & de Vet, H. C. W. (2012) · Quality of Life Research · doi:10.1007/s11136-011-9960-1 · Cited by 1,978
Developing core outcome sets for clinical trials: issues to consider
Williamson, P. R., Altman, D. G., Blazeby, J. M., Clarke, M., Devane, D., Gargon, E., & Tugwell, P. (2012) · Trials · doi:10.1186/1745-6215-13-132 · Cited by 1,661
Standardizing Patient Outcomes Measurement
Porter, M. E., Larsson, S., & Lee, T. H. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1511701 · Cited by 626
Hobart, J., & Cano, S. (2009) · Health Technology Assessment · doi:10.3310/hta13120 · Cited by 621
Self-citationWhy clinical trial outcomes fail to translate into benefits for patients
Heneghan, C., Goldacre, B., & Mahtani, K. R. (2017) · Trials · doi:10.1186/s13063-017-1870-2 · Cited by 404
Trends in clinical success rates
Smietana, K., Siatkowski, M., & Møller, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.85 · Cited by 277 · cited 1×
“Third, while encouraging overall clinical trial success rates for rare disease treatments are being reported [10, 11], recurrent late-stage drug development programme failures (e.”
BackgroundTowards the use of mixed methods inquiry as best practice in health outcomes research
On behalf of the International Society for Quality of Life Research (ISOQOL) Mixed Methods Special Interest Group (SIG), Regnault, A., Willgoss, T., & Barbic, S. (2018) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-018-0043-8 · Cited by 266 · cited 1×
“tive and quantitative research methods in tandem with the explicit aim to efficiently utilise data from small samples [42].”
BackgroundMobile health: the power of wearables, sensors, and apps to transform clinical trials
Munos, B., Baker, P. C., Bot, B. M., Crouthamel, M., de Vries, G., Ferguson, I., Hixson, J. D., Malek, L. A., Mastrototaro, J. J., Misra, V., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13117 · Cited by 118
Cited by
Palmer, E. E., Howell, K., & Scheffer, I. E. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01133-3 · Cited by 53
Chemaly, N., Kuchenbuch, M., Teng, T., Marie, E., D'Onofrio, G., Lo Barco, T., Brambilla, I., Flege, S., Hallet, A., & Nabbout, R. (2024) · Epilepsia Open · doi:10.1002/epi4.12557 · Cited by 20
Living With Frontotemporal Degeneration: Diagnostic Journey, Symptom Experiences, and Disease Impact
Barker, M. S., Dodge, S. G., Niehoff, D., Denny, S., Dacks, P. A., Dickinson, S., Cosentino, S., & Wheaton, D. K. H. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221119976 · Cited by 17
Metadata
- Authors
- Morel, T., & Cano, S. J.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2017-11-02
- Volume
- 12
- Issue
- 1
- Pages
- 171-171
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2766356879
- Cited by
- 194
- References
- 9
- FWCI
- 17.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. https://app.cochat.ai/papers/10.1186/s13023-017-0718-x
- The paper
- Morel, T., & Cano, S. J. (2017). Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-017-0718-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.